{"id":"https://openalex.org/W2921926643","doi":"https://doi.org/10.1017/s109285291900052x","title":"67 Effects of Long-term Valbenazine on Psychiatric Status in Patients with Tardive Dyskinesia and a Primary Mood Disorder","display_name":"67 Effects of Long-term Valbenazine on Psychiatric Status in Patients with Tardive Dyskinesia and a Primary Mood Disorder","publication_year":2019,"publication_date":"2019-02-01","ids":{"openalex":"https://openalex.org/W2921926643","doi":"https://doi.org/10.1017/s109285291900052x","mag":"2921926643"},"language":"en","primary_location":{"id":"doi:10.1017/s109285291900052x","doi":"https://doi.org/10.1017/s109285291900052x","is_oa":true,"landing_page_url":"https://doi.org/10.1017/s109285291900052x","pdf_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/B75883CAA80CF4484E5D9390D580CE40/S109285291900052Xa.pdf/div-class-title-67-effects-of-long-term-valbenazine-on-psychiatric-status-in-patients-with-tardive-dyskinesia-and-a-primary-mood-disorder-div.pdf","source":{"id":"https://openalex.org/S4210237982","display_name":"CNS Spectrums","issn_l":"1092-8529","issn":["1092-8529","2165-6509"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS Spectrums","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/B75883CAA80CF4484E5D9390D580CE40/S109285291900052Xa.pdf/div-class-title-67-effects-of-long-term-valbenazine-on-psychiatric-status-in-patients-with-tardive-dyskinesia-and-a-primary-mood-disorder-div.pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5068850044","display_name":"Roger S. McIntyre","orcid":"https://orcid.org/0000-0003-4733-2523","observed_orcids":["https://orcid.org/0000-0003-4733-2523"]},"institutions":[{"id":"https://openalex.org/I1338135719","display_name":"Centre for Addiction and Mental Health","ror":"https://ror.org/03e71c577","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1338135719"]},{"id":"https://openalex.org/I139290212","display_name":"Hofstra University","ror":"https://ror.org/03pm18j10","country_code":"US","type":"education","lineage":["https://openalex.org/I139290212"]},{"id":"https://openalex.org/I185261750","display_name":"University of Toronto","ror":"https://ror.org/03dbr7087","country_code":"CA","type":"education","lineage":["https://openalex.org/I185261750"]},{"id":"https://openalex.org/I4210106353","display_name":"Donald & Barbara Zucker School of Medicine at Hofstra/Northwell","ror":"https://ror.org/01ff5td15","country_code":"US","type":"education","lineage":["https://openalex.org/I1302444339","https://openalex.org/I139290212","https://openalex.org/I4210106353"]},{"id":"https://openalex.org/I4210166545","display_name":"Zucker Hillside Hospital","ror":"https://ror.org/05vh9vp33","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1302444339","https://openalex.org/I4210166545"]},{"id":"https://openalex.org/I4405280014","display_name":"Campbell Family Mental Health Research Institute","ror":"https://ror.org/02ab2j218","country_code":"CA","type":"facility","lineage":["https://openalex.org/I1338135719","https://openalex.org/I4405280014"]},{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["CA","US"],"is_corresponding":false,"raw_author_name":"Roger S. McIntyre","raw_affiliation_strings":["Director, Biostatistics and Data Management, Neurocrine Biosciences, Inc., San Diego, CA","Director, Medical Communications, Neurocrine Biosciences, Inc., San Diego, CA","Executive Director, Medical Affairs, Neurocrine Biosciences, Inc., San Diego, CA","Medical Communications Specialist, Neurocrine Biosciences, Inc., San Diego, CA","Medical Director, Neurocrine Biosciences, Inc., San Diego, CA","Medical Director, Recognition and Prevention (RAP) Program, The Zucker Hillside Hospital, Glen Oaks, NY and Professor of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY","Professor of Psychiatry and Pharmacology, Department of Psychiatry, University of Toronto","Senior Scientist in the Campbell Family Mental Health Research Institute and Chief of the Schizophrenia Division, Centre for Addiction and Mental Health","Toronto, Canada","Toronto, Ontario, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Director, Biostatistics and Data Management, Neurocrine Biosciences, Inc., San Diego, CA","institution_ids":["https://openalex.org/I67391869"]},{"raw_affiliation_string":"Director, Medical Communications, Neurocrine Biosciences, Inc., San Diego, CA","institution_ids":["https://openalex.org/I67391869"]},{"raw_affiliation_string":"Executive Director, Medical Affairs, Neurocrine Biosciences, Inc., San Diego, CA","institution_ids":["https://openalex.org/I67391869"]},{"raw_affiliation_string":"Medical Communications Specialist, Neurocrine Biosciences, Inc., San Diego, CA","institution_ids":["https://openalex.org/I67391869"]},{"raw_affiliation_string":"Medical Director, Neurocrine Biosciences, Inc., San Diego, CA","institution_ids":["https://openalex.org/I67391869"]},{"raw_affiliation_string":"Medical Director, Recognition and Prevention (RAP) Program, The Zucker Hillside Hospital, Glen Oaks, NY and Professor of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY","institution_ids":["https://openalex.org/I139290212","https://openalex.org/I4210106353","https://openalex.org/I4210166545"]},{"raw_affiliation_string":"Professor of Psychiatry and Pharmacology, Department of Psychiatry, University of Toronto","institution_ids":["https://openalex.org/I185261750"]},{"raw_affiliation_string":"Senior Scientist in the Campbell Family Mental Health Research Institute and Chief of the Schizophrenia Division, Centre for Addiction and Mental Health","institution_ids":["https://openalex.org/I1338135719","https://openalex.org/I4405280014"]},{"raw_affiliation_string":"Toronto, Canada","institution_ids":[]},{"raw_affiliation_string":"Toronto, Ontario, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022096029","display_name":"Gary J. Remington","orcid":"https://orcid.org/0000-0001-9433-9416","observed_orcids":["https://orcid.org/0000-0001-9433-9416"]},"institutions":[{"id":"https://openalex.org/I1338135719","display_name":"Centre for Addiction and Mental Health","ror":"https://ror.org/03e71c577","country_code":"CA","type":"healthcare","lineage":["https://openalex.org/I1338135719"]},{"id":"https://openalex.org/I4405280014","display_name":"Campbell Family Mental Health Research Institute","ror":"https://ror.org/02ab2j218","country_code":"CA","type":"facility","lineage":["https://openalex.org/I1338135719","https://openalex.org/I4405280014"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Gary Remington","raw_affiliation_strings":["Senior Scientist in the Campbell Family Mental Health Research Institute and Chief of the Schizophrenia Division, Centre for Addiction and Mental Health; Toronto, Ontario, Canada","Senior Scientist in the Campbell Family Mental Health Research Institute and Chief of the Schizophrenia Division, Centre for Addiction and Mental Health","Toronto, Ontario, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Senior Scientist in the Campbell Family Mental Health Research Institute and Chief of the Schizophrenia Division, Centre for Addiction and Mental Health; Toronto, Ontario, Canada","institution_ids":["https://openalex.org/I1338135719","https://openalex.org/I4405280014"]},{"raw_affiliation_string":"Senior Scientist in the Campbell Family Mental Health Research Institute and Chief of the Schizophrenia Division, Centre for Addiction and Mental Health","institution_ids":["https://openalex.org/I1338135719","https://openalex.org/I4405280014"]},{"raw_affiliation_string":"Toronto, Ontario, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056944189","display_name":"Christoph Ulrich Correll","orcid":"https://orcid.org/0000-0002-7254-5646","observed_orcids":["https://orcid.org/0000-0002-7254-5646","https://orcid.org/0000-0002-0868-4449"]},"institutions":[{"id":"https://openalex.org/I139290212","display_name":"Hofstra University","ror":"https://ror.org/03pm18j10","country_code":"US","type":"education","lineage":["https://openalex.org/I139290212"]},{"id":"https://openalex.org/I4210106353","display_name":"Donald & Barbara Zucker School of Medicine at Hofstra/Northwell","ror":"https://ror.org/01ff5td15","country_code":"US","type":"education","lineage":["https://openalex.org/I1302444339","https://openalex.org/I139290212","https://openalex.org/I4210106353"]},{"id":"https://openalex.org/I4210166545","display_name":"Zucker Hillside Hospital","ror":"https://ror.org/05vh9vp33","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1302444339","https://openalex.org/I4210166545"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christoph U. Correll","raw_affiliation_strings":["Medical Director, Recognition and Prevention (RAP) Program, The Zucker Hillside Hospital, Glen Oaks, NY and Professor of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Director, Recognition and Prevention (RAP) Program, The Zucker Hillside Hospital, Glen Oaks, NY and Professor of Psychiatry and Molecular Medicine, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY","institution_ids":["https://openalex.org/I139290212","https://openalex.org/I4210106353","https://openalex.org/I4210166545"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015717321","display_name":"Rachel B. Weber","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rachel Weber","raw_affiliation_strings":["Medical Communications Specialist, Neurocrine Biosciences, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Communications Specialist, Neurocrine Biosciences, Inc., San Diego, CA","institution_ids":["https://openalex.org/I67391869"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113065584","display_name":"Khodayar Farahmand","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Khodayar Farahmand","raw_affiliation_strings":["Director, Medical Communications, Neurocrine Biosciences, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Director, Medical Communications, Neurocrine Biosciences, Inc., San Diego, CA","institution_ids":["https://openalex.org/I67391869"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004612041","display_name":"Leslie Lundt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leslie Lundt","raw_affiliation_strings":["Medical Director, Neurocrine Biosciences, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Director, Neurocrine Biosciences, Inc., San Diego, CA","institution_ids":["https://openalex.org/I67391869"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051911390","display_name":"Joshua Burke","orcid":"https://orcid.org/0009-0009-7883-6610","observed_orcids":["https://orcid.org/0009-0009-7883-6610"]},"institutions":[{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joshua Burke","raw_affiliation_strings":["Director, Biostatistics and Data Management, Neurocrine Biosciences, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Director, Biostatistics and Data Management, Neurocrine Biosciences, Inc., San Diego, CA","institution_ids":["https://openalex.org/I67391869"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5076964650","display_name":"Scott W. K. Siegert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott Siegert","raw_affiliation_strings":["Executive Director, Medical Affairs, Neurocrine Biosciences, Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Executive Director, Medical Affairs, Neurocrine Biosciences, Inc., San Diego, CA","institution_ids":["https://openalex.org/I67391869"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2980,"currency":"USD","value_usd":2980},"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.02783344,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"24","issue":"1","first_page":"210","last_page":"211"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.6996999979019165,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.6996999979019165,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10854","display_name":"Bipolar Disorder and Treatment","score":0.20900000631809235,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.06539999693632126,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/valbenazine","display_name":"valbenazine","score":1.0},{"id":"https://openalex.org/keywords/tardive-dyskinesia","display_name":"tardive dyskinesia","score":1.0},{"id":"https://openalex.org/keywords/mood-disorders","display_name":"mood disorders","score":0.7770000100135803},{"id":"https://openalex.org/keywords/bipolar-disorder","display_name":"bipolar disorder","score":0.9980000257492065},{"id":"https://openalex.org/keywords/major-depressive-disorder","display_name":"major depressive disorder","score":0.9980000257492065},{"id":"https://openalex.org/keywords/mental-health-status","display_name":"mental health status","score":0.5450000166893005},{"id":"https://openalex.org/keywords/long-term-treatment","display_name":"long-term treatment","score":0.640999972820282},{"id":"https://openalex.org/keywords/manic-symptoms","display_name":"manic symptoms","score":0.5199999809265137},{"id":"https://openalex.org/keywords/depressive-symptoms","display_name":"depressive symptoms","score":0.9419999718666077},{"id":"https://openalex.org/keywords/antipsychotic-side-effects","display_name":"antipsychotic adverse effects","score":0.5199999809265137},{"id":"https://openalex.org/keywords/washout-period","display_name":"washout period","score":0.6159999966621399},{"id":"https://openalex.org/keywords/young-mania-rating-scale","display_name":"Young Mania Rating Scale","score":0.7139999866485596},{"id":"https://openalex.org/keywords/montgomery-asberg-depression-rating-scale","display_name":"Montgomery-Asberg Depression Rating Scale","score":0.8619999885559082}],"concepts":[{"id":"https://openalex.org/C2777089681","wikidata":"https://www.wikidata.org/wiki/Q4340609","display_name":"Young Mania Rating Scale","level":5,"score":0.8224416375160217},{"id":"https://openalex.org/C2779158372","wikidata":"https://www.wikidata.org/wiki/Q1546328","display_name":"Tardive dyskinesia","level":3,"score":0.7018627524375916},{"id":"https://openalex.org/C2776174506","wikidata":"https://www.wikidata.org/wiki/Q131755","display_name":"Bipolar disorder","level":3,"score":0.6615283489227295},{"id":"https://openalex.org/C2780051608","wikidata":"https://www.wikidata.org/wiki/Q42844","display_name":"Major depressive disorder","level":3,"score":0.6284559369087219},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5885295867919922},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.5775555968284607},{"id":"https://openalex.org/C2780733359","wikidata":"https://www.wikidata.org/wiki/Q331769","display_name":"Mood","level":2,"score":0.5724849700927734},{"id":"https://openalex.org/C2777134132","wikidata":"https://www.wikidata.org/wiki/Q188638","display_name":"Mood disorders","level":3,"score":0.556267499923706},{"id":"https://openalex.org/C2776809841","wikidata":"https://www.wikidata.org/wiki/Q185935","display_name":"Mania","level":4,"score":0.49684813618659973},{"id":"https://openalex.org/C2778609679","wikidata":"https://www.wikidata.org/wiki/Q4915474","display_name":"Bipolar I disorder","level":5,"score":0.46792200207710266},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4471908211708069},{"id":"https://openalex.org/C2776592573","wikidata":"https://www.wikidata.org/wiki/Q4086956","display_name":"Bipolar II disorder","level":4,"score":0.4154568910598755},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3216662108898163},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.1918017566204071},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.13487377762794495}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1017/s109285291900052x","doi":"https://doi.org/10.1017/s109285291900052x","is_oa":true,"landing_page_url":"https://doi.org/10.1017/s109285291900052x","pdf_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/B75883CAA80CF4484E5D9390D580CE40/S109285291900052Xa.pdf/div-class-title-67-effects-of-long-term-valbenazine-on-psychiatric-status-in-patients-with-tardive-dyskinesia-and-a-primary-mood-disorder-div.pdf","source":{"id":"https://openalex.org/S4210237982","display_name":"CNS Spectrums","issn_l":"1092-8529","issn":["1092-8529","2165-6509"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS Spectrums","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1017/s109285291900052x","doi":"https://doi.org/10.1017/s109285291900052x","is_oa":true,"landing_page_url":"https://doi.org/10.1017/s109285291900052x","pdf_url":"https://www.cambridge.org/core/services/aop-cambridge-core/content/view/B75883CAA80CF4484E5D9390D580CE40/S109285291900052Xa.pdf/div-class-title-67-effects-of-long-term-valbenazine-on-psychiatric-status-in-patients-with-tardive-dyskinesia-and-a-primary-mood-disorder-div.pdf","source":{"id":"https://openalex.org/S4210237982","display_name":"CNS Spectrums","issn_l":"1092-8529","issn":["1092-8529","2165-6509"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310311721","host_organization_name":"Cambridge University Press","host_organization_lineage":["https://openalex.org/P4310311721","https://openalex.org/P4310311702"],"host_organization_lineage_names":["Cambridge University Press","University of Cambridge"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CNS Spectrums","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320315137","display_name":"Neurocrine Biosciences","ror":"https://ror.org/05d84mm26"},{"id":"https://openalex.org/F4320320273","display_name":"University of Cambridge","ror":"https://ror.org/013meh722"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2921926643.pdf","grobid_xml":"https://content.openalex.org/works/W2921926643.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2904345201","https://openalex.org/W4365511373","https://openalex.org/W4367305144","https://openalex.org/W2767962972","https://openalex.org/W2984880439","https://openalex.org/W3198637393","https://openalex.org/W2987128386","https://openalex.org/W2921953453","https://openalex.org/W2922229369","https://openalex.org/W2600552492"],"abstract_inverted_index":{"Abstract":[0],"Objective":[1],"Valbenazine":[2],"is":[3],"approved":[4],"for":[5],"tardive":[6],"dyskinesia":[7],"(TD)":[8],"in":[9,44,66,85,155,235,263,280,297,309,329],"adults":[10],"based":[11],"on":[12,283],"clinical":[13],"trials":[14],"that":[15],"included":[16,221],"patients":[17,70,110,310],"with":[18,50,71,82,171,186,191,198,311,326],"mood":[19,74,83,174,200,206,237,240,299,316],"disorders":[20,84],"(e.g.,":[21],"bipolar":[22,187],"disorder,":[23,188,194],"major":[24,192],"depressive":[25,193],"disorder).":[26],"In":[27],"two":[28],"long-termphase":[29],"3":[30,33,87],"trials,":[31],"KINECT":[32,36,86,100],"(NCT02274558)":[34],"and":[35,99,131,142,159,195,226,231,313],"4":[37,101,196],"(NCT02405091),":[38],"sustained":[39],"TD":[40,312],"improvements":[41],"were":[42,59,78,124,163,184,286],"found":[43],"participants":[45,81,170,207,238],"who":[46,318],"received":[47,208,319],"once-daily":[48,327],"treatment":[49,128,325],"valbenazine":[51,328],"(40":[52],"or":[53,295,301],"80mg).":[54],"Data":[55,77],"from":[56,80,153,261],"these":[57],"studies":[58],"analyzed":[60,164],"post":[61],"hoc":[62],"to":[63,321,331],"evaluate":[64],"changes":[65,123,152,260,294],"psychiatric":[67,333],"status":[68],"of":[69,204,324],"a":[72,114,172,314],"primary":[73,173,315],"disorder.":[75,201],"Methods":[76],"pooled":[79],"(6-week":[88],"double-blind,":[89],"placebo-controlled":[90],"period;":[91,95],"42-week":[92],"double-blind":[93],"extension":[94],"4-week":[96,105],"drug-free":[97,106],"washout)":[98],"(48week":[102],"open-label":[103],"treatment;":[104,216],"washout).":[107],"At":[108],"screening,":[109],"must":[111],"have":[112],"had":[113],"Brief":[115],"Psychiatric":[116],"Rating":[117,139,145],"Scale":[118,140,146],"total":[119,157,233,265],"score":[120,158],"<50.":[121],"Mood":[122,304],"evaluated":[125],"after":[126],"long-term":[127],"(Week":[129,133],"48)":[130],"washout":[132],"52)":[134],"using":[135],"the":[136,156,168,254],"Young":[137],"Mania":[138],"(YMRS)":[141],"Montgomery-\u00c5sberg":[143],"Depression":[144],"(MADRS).":[147],"For":[148],"each":[149],"scale,":[150],"mean":[151,264],"baseline":[154,244,262],"individual":[160,281],"item":[161],"scores":[162,234,266],"descriptively.":[165],"Results":[166],"Of":[167],"95":[169],"disorder":[175,317],"(40mg":[176],",":[177,180],"n=32;":[178],"80mg":[179],"n=63),":[181],"59":[182],"(62.1%)":[183],"diagnosed":[185],"32":[189],"(33.7%)":[190],"(4.2%)":[197],"another":[199],"A":[202],"majority":[203],"all":[205,236],"concomitant":[209,219],"antidepressants":[210],"(84.2%)":[211],"and/or":[212],"antipsychotics":[213],"(76.8%)":[214],"during":[215,253],"other":[217],"common":[218],"medications":[220],"antiepileptics":[222],"(47.4%),":[223],"anxiolytics":[224],"(38.9%),":[225],"anticholinergics":[227],"(22.1%).":[228],"Mean":[229],"YMRS":[230],"MADRS":[232],"indicated":[239,257],"symptom":[241,305],"stability":[242,250,306],"at":[243],"(YMRS,":[245],"2.7;":[246],"MADRS,":[247],"5.9).":[248],"This":[249],"was":[251,307],"maintained":[252,308],"studies,":[255],"as":[256],"by":[258],"minimal":[259],"(YMRS:":[267],"Week":[268,271,275],"48,":[269,276],"1.0;":[270],"52,":[272],"\u20131.0;":[273],"MADRS:":[274],"0.3;":[277],"Week52,0.9).":[278],"Changes":[279],"items":[282],"both":[284],"scales":[285],"also":[287],"small":[288],"(<\u00b10.3),":[289],"indicating":[290],"no":[291],"clinically":[292],"significant":[293],"worsening":[296],"specific":[298],"symptoms":[300],"domains.":[302],"Conclusions":[303],"up":[320],"48":[322],"weeks":[323],"addition":[330],"their":[332],"medication(s).":[334],"Funding":[335],"Acknowledgements:":[336],"Neurocrine":[337],"Biosciences,":[338],"Inc.":[339]},"counts_by_year":[],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2019-03-22T00:00:00"}